What is it about?
To investigate more effective chemotherapy against hormone refractory prostate cancer (HRPC) with the combination of estramustine (EM), docetaxel, and suramin.
Featured Image
Photo by Quino Al on Unsplash
Why is it important?
Management of this hormone refractory stage of prostate cancer remains a significant challenge to the clinician.
Perspectives
The ultimate goal of a treatment of hormone refractory prostate cancer is the demonstration of prolongation of disease-related survival. The optimal therapy, if any, for HRPC patients with disease progression after hormone therapy is unknown. A relatively well tolerated agent, such as suramin, in combination with EM and docetaxel could be considered testing as moderately effective chemotherapy.
Dr Mohammad Reza Safarinejad
University of Medical Sceices
Read the Original
This page is a summary of: Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer, Urologic Oncology Seminars and Original Investigations, March 2005, Elsevier,
DOI: 10.1016/j.urolonc.2004.10.003.
You can read the full text:
Resources
Contributors
The following have contributed to this page
